The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18–40 years old: a possible HIV indicator condition
Open accessAbstract
Near 25% of the 38 million of people living with human immunodeficiency virus (HIV) infection are unaware of their HIV status 1 . Late diagnosis reduces treatment outcomes and increases healthcare costs and transmission rates. Routine testing for conditions that are considered indicators in an HIV prevalence of >0.1% is recognized to be cost-effective and has the potential to increase earlier diagnosis of HIV 2 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients exposed to certain agents (Agent Orange, pesticides, 9/11 World Trade Center dust) or suffering from specific conditions (HIV or Gaucher) have a higher prevalence of clonal populations.
“Importantly, it has also been demonstrated that patients exposed to certain agents (e.g. Agent Orange in Vietnam veterans, pesticides in agricultural worker, or 9/11 World Trade Center dust in first responders) or those suffering from specific conditions (such as HIV or Gaucher) have a higher prevalence of these clonal populations. 37-39 40,41 42”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Flagged first, then by citations
Research works printed but not linked: 7
- Sullivan, A. K. et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV Indicator Diseases across Europe Study). PLoS ONE 8, e52845 (2013). · DOI
- Raben, D. et al. Improving the evidence for indicator condition guided HIV testing in Europe: results from the HIDES II Study—2012–2015. PLoS ONE 14, e0220108 (2019). · DOI
- Pang, L. et al. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J. 11, 26 (2021). · DOI
- Castaneda-Avila, M. A., Ulbricht, C. M. & Epstein, M. M. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. Ann. Hematol. 100, 855–863 (2021). · DOI
- Genet P. et al. Prevalence of monoclonal gammopathy in HIV patients in 2014. J. Int. AIDS Soc. 17, 19649 (2014). · DOI
- Landgren O. et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 7, e618 (2017). · DOI
- Ouedraogo, D. E. et al. Pivotal role of HIV and EBV replication in the long-term persistence of monoclonal gammopathy in patients on antiretroviral therapy. Blood 122, 3030–3 (2013). · DOI
Cited by
Sorted by citations
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8
Metadata
- Authors
- Bibas, M., Pittalis, S., Orchi, N., De Carli, G., Agrati, C., Girardi, E., Antinori, A., Puro, V., & Ippolito, G.
- Affiliations
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Corresponding author
- Bibas, Michele
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2021-05-16
- Volume
- 11
- Issue
- 5
- Pages
- 91-91
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8126560
- OpenAlex
- W3163367094
- Cited by
- 8
- References
- 1
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 2
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-06-02)
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute (Ricerca Corrente LInea 2, Ricerca Corrente Linea 2)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- monoclonal gammopathy of undetermined significance, HIV, HIV diagnosis, prevalence, early HIV diagnosis, routine screening, young adults
- MeSH terms
- Adolescent, Adult, Female, HIV, Humans, Male, Monoclonal Gammopathy of Undetermined Significance, Retrospective Studies, Risk Factors, HIV Infections, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
